[Progress of epigenetics and its therapeutic application in hepatocellular carcinoma].

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Yi chuan = Hereditas

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.16288/j.yczz.14-443PMID 26351047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenetic therapy as a novel approach in hepatocellular carcinoma.

  2015cited by this paper
• RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.

  2014influential reference
• Promoter Methylation of MLH1, PMS2, MSH2 and p16 Is a Phenomenon of Advanced-Stage HCCs

  2014cited by this paper
• Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

  2014cited by this paper
• Epigenetic reprogramming modulates malignant properties of human liver cancer

  2014cited by this paper
• Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis

  2014cited by this paper
• Alterations of epigenetics and microRNA in hepatocellular carcinoma

  2014cited by this paper
• Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.

  2013influential reference
• Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma

  2013influential reference
• Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma

  2013cited by this paper
• DNA Methyltransferase Inhibitor Zebularine Inhibits Human Hepatic Carcinoma Cells Proliferation and Induces Apoptosis

  2013influential reference
• Long noncoding RNAs and the genetics of cancer

  2013cited by this paper
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.

  2013cited by this paper
• Hepatitis B virus X protein (HBx)‐related long noncoding RNA (lncRNA) down‐regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin

  2013influential reference
• Long Non-Coding RNAs: Challenges for Diagnosis and Therapies

  2013cited by this paper
• Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

  2012cited by this paper
• Genome‐wide DNA methylation profiles in hepatocellular carcinoma

  2012influential reference
• MicroRNA-141 Represses HBV Replication by Targeting PPARA

  2012cited by this paper
• Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

  2012cited by this paper
• Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells.

  2012cited by this paper
• HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

  2012cited by this paper
• Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

  2012influential reference
• Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation

  2012influential reference
• Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells.

  2012influential reference
• Genetics and epigenetics of liver cancer.

  2012influential reference
• Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells

  2012cited by this paper
• Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

  2012influential reference
• Elevation of Highly Up-regulated in Liver Cancer (HULC) by Hepatitis B Virus X Protein Promotes Hepatoma Cell Proliferation via Down-regulating p18*

  2012cited by this paper
• Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma.

  2012cited by this paper
• A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

  2012cited by this paper
• Targeted therapy of hepatocellular carcinoma: Present and future

  2012cited by this paper
• Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence‐free survival after hepatectomy

  2012cited by this paper
• Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

  2012influential reference
• Epigenetic mechanisms in anti‐cancer actions of bioactive food components – the implications in cancer prevention

  2012cited by this paper
• Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation

  2011influential reference
• Epigenetic diet: impact on the epigenome and cancer.

  2011cited by this paper
• Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.

  2011cited by this paper
• microRNA Replacement Therapy for Cancer

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• An HNF4a-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis

  2011cited by this paper
• High Expression of H3K27me3 in Human Hepatocellular Carcinomas Correlates Closely with Vascular Invasion and Predicts Worse Prognosis in Patients

  2011cited by this paper
• Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans

  2011influential reference
• The emergence of lncRNAs in cancer biology.

  2011cited by this paper
• Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription

  2010influential reference
• The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase

  2010influential reference
• An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer

  2010influential reference
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

  2010influential reference
• Hepatocellular Carcinoma Displays Distinct DNA Methylation Signatures with Potential as Clinical Predictors

  2010influential reference
• The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

  2010influential reference
• Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

  2009cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.

  2009influential reference
• MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma

  2009cited by this paper
• Title MicroRNA expression, survival, and response to interferon in liver cancer

  2009cited by this paper
• Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression

  2009influential reference
• MicroRNA involvement in hepatocellular carcinoma

  2008cited by this paper
• Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.

  2008influential reference
• LNA-mediated microRNA silencing in non-human primates

  2008cited by this paper
• Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007influential reference
• Surgical Treatment for Liver Cancer

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• Interferon modulation of cellular microRNAs as an antiviral mechanism

  2007cited by this paper
• Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

  2007cited by this paper
• Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications

  2006influential reference
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

  2006influential reference
• De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

  2006cited by this paper
• Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues

  2006influential reference
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas

  2006influential reference
• Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?

  2006influential reference
• Mammalian DNA methyltransferases.

  2006cited by this paper
• Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice

  2006cited by this paper
• Hepatocellular carcinoma: overcoming challenges in disease management.

  2006cited by this paper
• Silencing of microRNAs in vivo with ‘antagomirs’

  2005cited by this paper
• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

  2005cited by this paper
• A Cellular MicroRNA Mediates Antiviral Defense in Human Cells

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Drug reactivates genes to inhibit cancer.

  2003cited by this paper
• DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells

  2003cited by this paper
• Identification of tissue-specific microRNAs from mouse.

  2002cited by this paper
• Hepatocellular carcinoma.

  1986influential reference

• Construction and validation of an N6-methyladenosine-associated prognostic signature in hepatocellular carcinoma

  2021cites this paper
• A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation.

  2020cites this paper
• M 6A-related genes characterization in hepatocellular cancer identifies prognostic relevant gene signatures

  2020cites this paper
• miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling

  2017cites this paper